Skip to main content
. 2024 Dec 18;14:1451308. doi: 10.3389/fcimb.2024.1451308

Table 3.

HPV antibody geometric mean concentrations (GMC)* for the 4vHPV vaccine-types (6, 11, 16, and 18), and for the additional five types included in the 9vHPV vaccine (31, 33, 45, 52, and 58), before and after the 4th dose, among the 23 study participants (22 solid organ transplant recipients and 1 with systemic lupus erythematosus) who had not seroconverted for at least one HPV vaccine type after the third dose), considering the HPV types for which they had seroconverted.

HPV serotype n Post 3rd dose GMC (95%CI) n Pre 4th dose GMC (95%CI) n Post 4th dose GMC (95%CI) n GMC Ratio (Post/Pre 4th dose)
(95%CI)
n GMC Ratio (Post4rd/Post 3th dose)
(95%CI)
HPV 6 7 0.82 (0.14 – 4.67) 12 0.21 (0.11 – 0.38) 14 1.42 (0.3 – 6.68) 14 7,1 (1.72 – 29.1) 6 4.83 (0.21 – 113.37)
HPV 11 11 0.31 (0.15 – 0.65) 10 0.75 (0.19 – 0.30) 14 0.31 (0.049 – 1.99) 10 13.15 (2.31 – 74.88) 9 2.82 (0.35 – 22.72)
HPV 16 12 4.6 (1.1 – 19.19) 11 6.02 (1.52 – 23.84) 15 44.63 (6.87 – 289.76) 14 13.18 (3.89 – 44.68) 11 16.06 (2.89 – 89.29)
HPV 18 3 4.2 (0.63 – 278.91) 4 3.48 (0.39 – 31.04) 9 9.34 (1.78 – 49.07) 2 14.47 ** 2 3.91 (1.53 – 9.99)
HPV 31 2 1.37 (0.07 – 286.16) 7 0.35 (0.9 – 1.33) 9 1.39 (0.1 – 18.85) 8 4.49 (0.33 – 60.6) 2 24.92**
HPV 33 2 0.13** 3 0.26 (0.18 – 0.37) 3 1.00 (0.49 – 20.33) 3 3.33 (0.15 – 75.47) 1 1.14**
HPV 45 No values 5 0.38 (0.21 – 0.68) 5 1.17 (0.41 – 3.34) 3 4.29 (0.18 – 99.63) No values
HPV 52 5 2.58 (1.44 – 4.64) 1 0.89 2 0.85** 1 2.38** 1 1.16**
HPV 58 3 0.38 (0.01 – 119.62) 3 0.67 (0.07 – 66.12) 5 0.93 (0.28 – 3.04) 3 2.68 (0.05 – 153.74) 3 2.6 (0.15 – 44.77)

Only participants with positive serology were included in GMC calculations.

CI, confidence interval.

*Anti-HPV multiplexed pseudovirion-based serological assay (PsV-Luminex); GMC reported in International Units (IU).

**CI not established due to the small sample size.